KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Amortization of Deferred Charges (2016 - 2023)

Supernus Pharmaceuticals (SUPN) has disclosed Amortization of Deferred Charges for 13 consecutive years, with $532000.0 as the latest value for Q1 2023.

  • On a quarterly basis, Amortization of Deferred Charges rose 6.4% to $532000.0 in Q1 2023 year-over-year; TTM through Dec 2023 was $532000.0, a 74.81% decrease, with the full-year FY2023 number at $532000.0, down 74.81% from a year prior.
  • Amortization of Deferred Charges was $532000.0 for Q1 2023 at Supernus Pharmaceuticals, down from $583000.0 in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $4.5 million in Q4 2021 to a low of $500000.0 in Q1 2022.
  • A 5-year average of $3.1 million and a median of $4.0 million in 2019 define the central range for Amortization of Deferred Charges.
  • Peak YoY movement for Amortization of Deferred Charges: skyrocketed 528.76% in 2019, then crashed 88.41% in 2022.
  • Supernus Pharmaceuticals' Amortization of Deferred Charges stood at $4.0 million in 2019, then grew by 4.32% to $4.2 million in 2020, then rose by 6.77% to $4.5 million in 2021, then plummeted by 86.94% to $583000.0 in 2022, then fell by 8.75% to $532000.0 in 2023.
  • Per Business Quant, the three most recent readings for SUPN's Amortization of Deferred Charges are $532000.0 (Q1 2023), $583000.0 (Q4 2022), and $529000.0 (Q3 2022).